Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
European Journal of Cancer2017Vol. 75, pp. 24–32
Citations Over TimeTop 1% of 2017 papers
Ralf Gutzmer, Anika Koop, Friedegund Meier, Jessica C. Hassel, Patrick Terheyden, Lisa Zimmer, Lucie Heinzerling, Selma Ugurel, Claudia Pföhler, Anja Gesierich, Elisabeth Livingstone, Imke Satzger, Katharina C. Kähler
Related Papers
- → Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels(2014)57 cited
- → The Ipilimumab Lesson in Melanoma: Achieving Long-Term Survival(2015)28 cited
- → Ipilimumab in anti-PD1 refractory metastatic melanoma(2015)18 cited
- → Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma(2021)3 cited
- → Treatment Patterns among Advanced Melanoma Patients in Europe(2016)